Immutep (XTER:YP1A) Buildings And Improvements : €0.44 Mil (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Immutep Buildings And Improvements?

Immutep's quarterly buildings and improvements declined from Jun. 2023 (€0.24 Mil) to Sep. 2023 (€0.00 Mil) but then increased from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€0.44 Mil).

Immutep's annual buildings and improvements increased from Jun. 2021 (€0.17 Mil) to Jun. 2022 (€0.18 Mil) and increased from Jun. 2022 (€0.18 Mil) to Jun. 2023 (€0.24 Mil).

Immutep Buildings And Improvements Historical Data

The historical data trend for Immutep's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Buildings And Improvements Chart

Immutep Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Buildings And Improvements

Get a 7-Day Free Trial

0.12

0.17

0.18

0.24

Immutep Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Buildings And Improvements	Get a 7-Day Free Trial															-	-	0.24	-	0.44

Immutep Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Immutep (XTER:YP1A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (XTER:YP1A) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

PRRUF:USA IMMP:USA YP1B:Germany IMM:Australia

Address

264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000

Website

https://www.immutep.com

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Immutep (XTER:YP1A) Headlines

No Headlines